Advocacy Update – May 2023: What Does the End of the Public Health Emergency Mean for Medicaid?
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreLatest News
Updated COVID-19 Recommendations from UMDF’s Science & Medical Advisory Board – May 2023
COVID-19 updates 2023 Although the COVID-19 pandemic is declared over, the COVID-19 virus is still causing illness and death in the United...
Read moreResearch Update from 2013 UMDF Grant Recipient James Stewart, PhD
Funding nearly $15 million in research – research that is often underfunded but critical to the diagnosis and treatment of patients with...
Read moreAsk the Mito Doc – April 2023; Q&A: Endocrine Complications of Mitochondrial Disease
Ask the Mito Doc April 2023 Endocrine Complications of Mitochondrial Disease Clinician: Shana McCormack, MD, MTR, Children’s Hospital of...
Read moreAdvocacy Update – April 2023: Spring on Capitol Hill
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreAlpers syndrome
What is Alpers syndrome? Alpers syndrome is a mitochondrial disease that primarily affects the brain, vision, muscles, and liver. It goes by...
Read moreAsk the Mito Doc – February 2023: Cardiac Disease and the Mitochondrial Patient
Ask the Mito Doc February 2023 Cardiac Disease and the Mitochondrial Patient Clinicians: Hilary Vernon, MD, PhD, Reid Thompson MD, Rebecca...
Read moreAsk the Mito Doc – March 2023; Q&A: Clinical Trial Readiness and Emerging Therapies for Primary Mitochondrial Disease
Ask the Mito Doc March 2023 Clinical Trial Readiness and Emerging Therapies for Primary Mitochondrial Disease Clinician: Dr. Mary Kay Koenig...
Read moreAdvocacy Update – March 2023: Federal Appropriations 101 and Why Advocacy Matters for Mito
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreReata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omaveloxolone) for Friedreich’s Ataxia. Learn What this Means for the Mito Community.
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation Company to...
Read more